Tags : prabotulinumtoxinA-xvfs

Evolus’ Jeuveau (prabotulinumtoxinA-xvfs) Receives FDA Approval for Moderate-to-Severe Glabellar Lines

Shots: The approval is based on four P-III trials including two (EV-001 & EV-002) US trials and European & Canadian i.e TRANSPARENCY study results assessing Jeuveau vs PBO & Botox respectively in 2,100 patients with glabellar lines due to corrugator or procerus muscle activity in adults The TRANSPARENCY study collectively resulted in meeting 1EPs (67.5%, 70.4% […]Read More